Targeting tumor vessels is proving to be an effective approach in cancer therapy. In addition to the administration of anti-angiogenic drugs, a complementary strategy is to use vascular disrupting agents to damage tumor endothelial cells, which directly shuts down tumor vascular perfusion. Our preliminary studies show that the stilbene derivative, Stilbene 5c, can effectively suppress tumor vascular perfusion without compromising normal organ perfusion. However, stilbene used as a single agent has only marginal therapeutic efficacy in xenograft models. We propose to investigate the mechanism(s) of tumor vascular suppression and compensatory tumor mechanisms that occur after stilbene treatment.
Specific aim 1 is to study how stilbene suppresses tumor blood flow. Various imaging modalities, including high frequency ultrasound, luciferase imaging, and the use of oxygen blood flow sensors as well as assessment of tumor vascular density will be used to investigate tumor blood flow after stilbene treatment.
Specific aim 2 will investigate the rebound phenomenon observed in our preliminary studies. In particular, the work will focus on the contribution of nitric oxide-induced vasodilatation.
Specific aim 3 will investigate the roles of HIF-a and VEGF on the effectiveness of stilbene 5c. We will quantify the levels of circulating endothelial progenitor cells and use small interfering RNA to down-regulate HIF-a and VEGF to assess their involvement in mobilization of endothelial progenitor cells and influence on therapeutic efficacy of stilbene 5c. Successful completion of this study will serve to elucidate the mechanisms of action and compensatory responses to a new class of vascular disrupting agents with the goal of facilitating their future clinical application.

Public Health Relevance

Vascular disrupting agents are a new approach under development to treat cancer. However, tumor could develop various coping responses to compensate the effect of vascular disrupting agents. This study proposes to investigate the mechanism of vascular disrupting agents and examine the compensatory effect of tumor so that we can develop effective strategies to use them clinically.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Virginia Commonwealth University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Aziz, Najib; Detels, Roger; Chang, L Cindy et al. (2016) Macrophage Inflammatory Protein-3 Alpha (MIP-3?)/CCL20 in HIV-1-Infected Individuals. J AIDS Clin Res 7:
Alotaibi, M R; Asnake, B; Di, Xu et al. (2013) Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death. Biochem Pharmacol 86:1688-98
Da, Chenxiao; Mooberry, Susan L; Gupton, John T et al. (2013) How to deal with low-resolution target structures: using SAR, ensemble docking, hydropathic analysis, and 3D-QSAR to definitively map the **-tubulin colchicine site. J Med Chem 56:7382-95
Biggers, Jonathan W; Nguyen, Tuyen; Di, Xu et al. (2013) Autophagy, cell death and sustained senescence arrest in B16/F10 melanoma cells and HCT-116 colon carcinoma cells in response to the novel microtubule poison, JG-03-14. Cancer Chemother Pharmacol 71:441-55
Da, Chenxiao; Telang, Nakul; Hall, Kayleigh et al. (2013) Developing novel C-4 analogues of pyrrole-based antitubulin agents: weak but critical hydrogen bonding in the colchicine site. Medchemcomm 4:417-421
Bristol, Molly L; Emery, Sean M; Maycotte, Paola et al. (2013) Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther 344:544-52
Da, Chenxiao; Telang, Nakul; Barelli, Peter et al. (2012) Pyrrole-Based Antitubulin Agents: Two Distinct Binding Modalities are Predicted for C-2 Analogs in the Colchicine Site. ACS Med Chem Lett 3:53-57